Plasma Microrna-720 May Predict Prognosis and Diagnosis in Glioma Patients.

Peng Chen,Guangying Zhang,Qin Zhou,Zhanzhan Li
DOI: https://doi.org/10.1042/bsr20201449
2020-01-01
Bioscience Reports
Abstract:Abstract We enrolled 122 patients with glioma who received surgery treatment in our hospital from June 2010 to May 2012, and 60 healthy individuals. We found that the plasma miR-720 in the glioma group was significantly higher than that in the healthy control group (3.19 ± 1.26 vs 0.98 ± 0.65, P<0.001). The sensitivity and specificity were 71.3% (95%CI: 62.4–79.1%) and 83.3% (71.5–91.7%), respectively. The results indicated that the plasma miR-720 level was associated with tumor grade (t = 104.418, P<0.001). The advanced tumor tended to have higher miR-720 expression level. No significant association was found between miR-720 and age, sex, tumor size, KPS and tumor position (P=0.438, 0.514, 0.518, 0.058, 0.226). The multivariate cox analysis indicated that the high expression of miR-720 (HR = 1.48, 95%CI: 1.12–2.97, P=0.023) was independently predictors of adverse prognosis in patients with glioma. The high expression of miR-720 was also associated with recurrence or development in patients with glioma (HR = 1.47, 95%CI: 1.18–3.14, P=0.012). Plasma miR-720 has a moderate diagnostic ability in early diagnostic of glioma and may be a potential tumor biomarker. The high plasma miR-720 was related to adverse prognosis in patients with glioma and could be a prognosis predictor of glioma patients.
What problem does this paper attempt to address?